Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Testosterone Undecanoate

FDA-approved product (injectable, intramuscular), marketed as Aveed, Jatenzo, Kyzatrex and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Testosterone Undecanoate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Hypogonadism
  • Hypogonadotropic hypogonadism
  • Klinefelter's syndrome
  • Neoplasm
  • Orchitis
  • Physiological sexual disorder
  • Sexual dysfunction

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
3-oxoandrosten (4) derivatives
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA51.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli28.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae27.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis24.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Testosterone Undecanoate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Testosterone Undecanoate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Effect of Testosterone on Elderly Frail Men With Testosterone Deficiency

    NCT07512323 · start 2026-08-01

    Registered record
    Registry ID
    NCT07512323
    Conditions
    Frail Elderly Patients; Hypogonadal Males; Testosterone Replacement Therapy; Falls (Accidents) in Old Age
    Interventions
    Nebido (Testosterone Undecanoate)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-08-01
    Completion
    2030-09-30
    Enrolment
    96

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFrail Elderly Patients; Hypogonadal Males; Testosterone Replacement Therapy; Falls (Accidents) in Old Age
    InterventionNebido (Testosterone Undecanoate)
    PhasePhase 2
    Registry statusNot yet recruiting

  • Testosterone-induced Muscle Memory and Underlying Mechanisms

    NCT06188767 · start 2025-04-01

    Registered record
    Registry ID
    NCT06188767
    Conditions
    Skeletal Muscle Physiology
    Interventions
    Testosterone Undecanoate
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2025-04-01
    Completion
    2028-12-01
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSkeletal Muscle Physiology
    InterventionTestosterone Undecanoate
    PhaseNot applicable
    Registry statusRecruiting

  • An Open-Label Study of 50 Mg Oral Testosterone Undecanoate (Kyztrex) in Menopausal Women with Low Testosterone and HSDD

    NCT06082817 · start 2025-01-01

    Registered record
    Registry ID
    NCT06082817
    Conditions
    Hypoactive Sexual Desire Disorder
    Interventions
    Oral Testosterone Undecanoate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2025-01-01
    Completion
    2025-12-31
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypoactive Sexual Desire Disorder
    InterventionOral Testosterone Undecanoate
    PhasePhase 2
    Registry statusNot yet recruiting

  • Comparing Direct and Indirect Detection Methods of Multiple Routes of Testosterone Administration

    NCT06393634 · start 2024-11-27

    Registered record
    Registry ID
    NCT06393634
    Conditions
    Healthy
    Interventions
    Testosterone injection; Testosterone gel; Testosterone Oral
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2024-11-27
    Completion
    2024-11-27
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionTestosterone injection; Testosterone gel; Testosterone Oral
    PhaseEarly phase 1
    Registry statusCompleted

  • Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer

    NCT05081193 · start 2022-03-07

    Registered record
    Registry ID
    NCT05081193
    Conditions
    Prostate Cancer; Castration-resistant Prostate Cancer; Metastatic Castration-resistant Prostate Cancer
    Interventions
    Testosterone Undecanoate; Enzalutamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2022-03-07
    Completion
    2025-08-04
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer; Castration-resistant Prostate Cancer; Metastatic Castration-resistant Prostate Cancer
    InterventionTestosterone Undecanoate; Enzalutamide
    PhasePhase 2
    Registry statusCompleted

  • Testosterone Undecanoate Replacement Therapy in Boys With Pubertal Delay or Confirmed Hypogonadism

    NCT05541172 · start 2022-03-01

    Registered record
    Registry ID
    NCT05541172
    Conditions
    Delayed Puberty; Male Hypogonadism
    Interventions
    Testosterone Undecanoate
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2022-03-01
    Completion
    2025-12-31
    Enrolment
    27

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDelayed Puberty; Male Hypogonadism
    InterventionTestosterone Undecanoate
    PhaseNot recorded
    Registry statusUnknown

  • Pain Alleviation With Testosterone in Opioid-Induced Hypogonadism

    NCT04798469 · start 2022-01-10

    Registered record
    Registry ID
    NCT04798469
    Conditions
    Opioid Use; Pain; Hypogonadism, Male
    Interventions
    Testosterone Undecanoate 250 MG/ML; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2022-01-10
    Completion
    2027-12-30
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpioid Use; Pain; Hypogonadism, Male
    InterventionTestosterone Undecanoate 250 MG/ML; Placebo
    PhasePhase 2
    Registry statusRecruiting

  • Patient Satisfaction After Switching to Oral Testosterone Undecanoate

    NCT04983940 · start 2021-06-18

    Registered record
    Registry ID
    NCT04983940
    Conditions
    Testosterone Deficiency
    Interventions
    Jatenzo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2021-06-18
    Completion
    2023-04-06
    Enrolment
    41

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTestosterone Deficiency
    InterventionJatenzo
    PhasePhase 4
    Registry statusCompleted

  • Testosterone Replacement in Male Cancer Survivors With Fatigue and Low Testosterone

    NCT04049331 · start 2021-03-22

    Registered record
    Registry ID
    NCT04049331
    Conditions
    Hypogonadism, Male; Fatigue Syndrome, Chronic
    Interventions
    Testosterone Undecanoate 750 MG/3 ML Intramuscular Solution [AVEED]; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2021-03-22
    Completion
    2027-01-30
    Enrolment
    240

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypogonadism, Male; Fatigue Syndrome, Chronic
    InterventionTestosterone Undecanoate 750 MG/3 ML Intramuscular Solution [AVEED]; placebo
    PhasePhase 2
    Registry statusRecruiting

  • A Study of the Safety and Tolerability of LPCN 1144 in Subjects Who Completed the LPCN 1144-18-002 Trial

    NCT04685993 · start 2020-11-11

    Registered record
    Registry ID
    NCT04685993
    Conditions
    NASH - Nonalcoholic Steatohepatitis
    Interventions
    LPCN 1144
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2020-11-11
    Completion
    2022-03-01
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNASH - Nonalcoholic Steatohepatitis
    InterventionLPCN 1144
    PhasePhase 2
    Registry statusCompleted

  • The Effects of Semaglutide vs Testosterone Replacement Therapy on Functional Hypogonadism and Sperm Quality in Men With Type 2 Diabetes Mellitus and Obesity

    NCT06489457 · start 2020-09-20

    Registered record
    Registry ID
    NCT06489457
    Conditions
    Type 2 Diabetes Mellitus; Obesity; Functional Hypogonadism
    Interventions
    Semaglutide; Testosterone Undecanoate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2020-09-20
    Completion
    2023-06-30
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus; Obesity; Functional Hypogonadism
    InterventionSemaglutide; Testosterone Undecanoate
    PhasePhase 3
    Registry statusCompleted

  • A Study of the Effect of Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With Hypogonadism

    NCT04456296 · start 2020-06-30

    Registered record
    Registry ID
    NCT04456296
    Conditions
    Hypogonadism; Hypogonadism, Male; Hypogonadotropic Hypogonadism
    Interventions
    Aveed Injectable Product; Fortesta; Testim
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2020-06-30
    Completion
    2023-07-12
    Enrolment
    673

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypogonadism; Hypogonadism, Male; Hypogonadotropic Hypogonadism
    InterventionAveed Injectable Product; Fortesta; Testim
    PhasePhase 4
    Registry statusCompleted

  • Trial of Testosterone Undecanoate for Optimizing Performance During Military Operations

    NCT04120363 · start 2019-09-23

    Registered record
    Registry ID
    NCT04120363
    Conditions
    Caloric Restriction; Exercise; Sleep
    Interventions
    Testosterone Undecanoate; Sesame Oil
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2019-09-23
    Completion
    2021-07-08
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCaloric Restriction; Exercise; Sleep
    InterventionTestosterone Undecanoate; Sesame Oil
    PhasePhase 4
    Registry statusCompleted

  • Multimodality Intervention for Function and Metabolism in SCI

    NCT03576001 · start 2019-08-23

    Registered record
    Registry ID
    NCT03576001
    Conditions
    Spinal Cord Injuries
    Interventions
    Testosterone Undecanoate; hybrid exercise
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-08-23
    Completion
    2025-03-30
    Enrolment
    84

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSpinal Cord Injuries
    InterventionTestosterone Undecanoate; hybrid exercise
    PhasePhase 2
    Registry statusCompleted

  • Efficacy and Safety of Testosterone Therapy in Improving Sarcopenia in Men With Cirrhosis.

    NCT03995251 · start 2019-07-04

    Registered record
    Registry ID
    NCT03995251
    Conditions
    Liver Cirrhosis
    Interventions
    Testosterone Supplementation; Standard Medical Treatment; Exercise
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2019-07-04
    Completion
    2020-06-30
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Cirrhosis
    InterventionTestosterone Supplementation; Standard Medical Treatment; Exercise
    PhaseNot applicable
    Registry statusUnknown